Quantcast

Latest UCB Stories

2009-10-09 23:01:00

PHILADELPHIA, October 10 /PRNewswire-FirstCall/ -- For U.S. Media Only - U.S. women living with rheumatoid arthritis demand more 'good days' - 68 percent of women living with rheumatoid arthritis look for new pain relief therapies to help them cope - Almost 60 percent of women in the U.S. living with rheumatoid arthritis find intimate relations painful - Rheumatoid arthritis played a role in 25 percent of divorces amongst women with the disease A new survey...

2009-09-02 05:00:00

SANTA MONICA, Calif., Sept. 2 /PRNewswire/ -- MTV has tapped hip-hop's newest challenger, Wale and the legendary go-go band UCB as the official house band for the 2009 VMAs, providing the night's soundtrack for the hottest music awards show this year. Not only will Wale perform his new hit single "World Tour," but he will also collaborate with artists including The All-American Rejects, Pitbull and 3OH!3 while putting his own unique spin on some of the biggest songs of the year. "This...

2009-08-26 11:51:00

EL PASO, Texas, Aug. 26 /PRNewswire-FirstCall/ -- Helen of Troy Limited (Nasdaq: HELE) designer, developer and worldwide marketer of brand-name personal care and household consumer products, today announced that the Company's OXO Housewares Division, along with its design partners, Smart Design and the Brussels-based biopharmaceutical company UCB, have been awarded the Red Dot Communication Design award for packaging used for the rheumatoid arthritis drug Cimzia. Gerald J. Rubin, Chairman,...

2009-06-24 15:30:00

Preliminary top-line results of second Phase III study show highly significant decreases in pain and fatigue and improved daily function in fibromyalgia patients and confirm results from the first Phase III study PALO ALTO, Calif., and BRUSSELS, June 24 /PRNewswire-FirstCall/ -- press release, regulated information -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) and UCB (Euronext Brussels: UCB) announced today positive preliminary top-line results from the second of two Phase III clinical...

2009-06-24 09:29:00

ALLEGAN, Mich., June 24 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that its partner Synthon Pharmaceuticals, Inc. has filed an Abbreviated New Drug Application (ANDA) for Levocetirizine solution 2.5mg/5ml, a generic version of Xyzal(R) solution 2.5mg/5ml. Under terms of an exclusive agreement between the companies, Perrigo has sales and marketing rights in Synthon's Levocetirizine products. The Company believes that Synthon is the first to file an ANDA...

2009-06-09 08:00:00

Overall Market Will Increase by a Modest $300 Million From 2008 to 2018, According to a New Report from Decision Resources WALTHAM, Mass., June 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that growth in the Parkinson's disease drug market, fueled by the launch of several new therapies through 2018, will be offset by generic erosion of key currently-available agents. As a result, sales of...

2009-06-01 08:07:00

CHICAGO, June 1 /PRNewswire/ -- UCB, Inc. and the Crohn's Disease Working Group (CDWG) today announced the four recipients of the 2009 Research Awards in Inflammatory Bowel Disease (IBD) for Gastroenterology (GI) Fellows, who each will receive a one-year research grant for their original clinical or basic research, totaling $175,000 for all four grants. The recipients were selected by the CDWG Steering Committee and the awards were funded by a grant from UCB. A reception honoring the...

2009-05-26 15:51:00

ATLANTA, May 26 /PRNewswire/ -- About Dr. Harold Kohn & Vimpat Almost twenty years after discovering a new chemical compound that affects neurological systems, Harold Kohn, Ph.D., University of North Carolina at Chapel Hill, inventor of the recently FDA-approved Vimpat(R) (lacosamide)C-V, meets Veronica Crowe, whose life has changed significantly with the use of the drug. Dr. Kohn was moved to hear her story of perseverance, and Veronica was thrilled to thank the man whose discovery...

2009-05-26 15:23:00

ATLANTA, May 26 /PRNewswire/ -- Vimpat(R) (lacosamide) C-V, a new antiepileptic drug (AED), will be available in U.S. pharmacies by the first week of June 2009. Vimpat was approved by the U.S. FDA in the fall of 2008 for the use as an add-on therapy for the treatment of partial-onset seizures in people 17 years and older with epilepsy. (Photo: http://www.newscom.com/cgi-bin/prnh/20090526/NY22555 ) Vimpat approval is based on safety and efficacy data from three pivotal trials with...

2009-05-15 06:00:00

Cimzia(R) (certolizumab pegol) now offered in an innovative prefilled syringe designed in partnership with OXO GOOD GRIPS(R) ATLANTA, May 15 /PRNewswire/ --- UCB today announced that Cimzia(R) (certolizumab pegol), the only PEGylated anti-TNF (Tumor Necrosis Factor) approved in the U.S. for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderate to severe active disease who have had an inadequate response to conventional therapy, is...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related